AI Analysis | Feedback

1. Think of it like a publicly traded private equity fund, but with one job: to find and acquire an established beauty or wellness company to bring into the public market.

2. It's similar to a "fast-track IPO" service, a public company formed specifically as a vehicle for a private beauty or wellness brand to quickly become publicly traded.

3. Imagine a specialized "talent scout" for the beauty and wellness industry, but instead of finding individuals, it's a public company looking to discover and acquire an entire promising brand to elevate to the public stage.

AI Analysis | Feedback

• Business Combination Facilitation: Identifying and executing mergers, acquisitions, or similar business combinations with target companies, primarily in the beauty, personal care, and wellness sectors, to bring them public.

AI Analysis | Feedback

Based on the provided background information, Waldencast Acquisition Corp. (WALD) is a Special Purpose Acquisition Company (SPAC) that does not currently have significant operations or sell products/services. Its primary purpose is to effect a business combination with one or more businesses. Therefore, Waldencast does not currently have major customers in the traditional sense.

AI Analysis | Feedback

AI Analysis | Feedback

Michel Brousset, Chief Executive Officer

Michel Brousset is the founder and CEO of Waldencast, established in 2019. He possesses over 25 years of operational expertise in the Fast-Moving Consumer Goods (FMCG) sector, having successfully built billion-dollar brands and businesses at Procter & Gamble and L'Oréal. At L'Oréal, he served as CEO of L'Oréal UK and subsequently as President of the Consumer Product Division for North America. Waldencast operates as an acquisition platform, and under his leadership, it undertook a $1.2 billion three-way combination with skincare and cosmetics brands Obagi and Milk Makeup.

Manuel Manfredi, Chief Financial Officer

Manuel Manfredi joined Waldencast as Chief Financial Officer on April 1, 2024. He brings nearly 25 years of experience leading financial organizations in the beauty and consumer products industries. Prior to Waldencast, he served as CFO at L'Oréal Spain and Portugal since 2022. His tenure at L'Oréal also included CFO roles for Italy (2019-2022) and Spain (2015-2019), as well as other senior financial positions managing multi-billion-dollar businesses across Europe and North America. Manfredi began his finance career at Procter & Gamble Europe in 1998, and while at L'Oréal, he played a key role in the acquisition and integration of a new cosmetics brand.

Hind Sebti, Founder & Chief Growth Officer

Hind Sebti is a co-founder of Waldencast and also the founder of the beauty and skincare brand Whind, which was the first beauty brand incubated under Waldencast. She has over 20 years of beauty-specific operational experience, gained during her time at L'Oréal and Procter & Gamble, where she led iconic brands such as Olay, L'Oréal Paris, and Maybelline. In July 2021, she became the first Arab woman co-founder of a Nasdaq-listed company following Waldencast's acquisition of Obagi and Milk Makeup.

Felipe Dutra, Co-Founder & Executive Chairman

Felipe Dutra is a co-founder and the Executive Chairman of Waldencast. He previously served as Chief Financial and Technology Officer at Anheuser-Busch InBev (AB InBev) from 2004 to 2020. In this role, he was instrumental in transforming AB InBev from a regional Brazilian brewer into the world's largest brewer. His career at Ambev (a predecessor to AB InBev) began in 1990, where he held various treasury and finance positions before becoming CFO in 1999. He also served as a Board Director for Grupo Modelo, Budweiser APAC, and AMBEV. AB InBev was formed through a series of mergers, highlighting his extensive involvement in large-scale corporate growth and M&A activities.

AI Analysis | Feedback

The most significant risk to Waldencast is its **financial distress and high leverage, compounded by declining revenue and significant profitability challenges.** The company's Altman Z-Score indicates financial distress, and it reported a net loss of $248.1 million for the year ended 2025, primarily due to impairment charges on Obagi Medical and Milk Makeup, depreciation and amortization, and financing costs. Waldencast has experienced a three-year revenue growth decline of 48%, with a deeply negative net margin of -73.5%, indicating substantial profitability issues. Furthermore, the company carries a high net debt of $186.6 million, resulting in a Net Debt/adjusted EBITDA ratio between 7.6 and 11.6x, which is considered very high for a company not generating positive EBIT.

A second key risk is the **underperformance of the Milk Makeup brand.** This segment's challenges have contributed to Waldencast facing flat FY 2025 revenue guidance, persistent execution issues, and elevated leverage. The company has incurred impairment charges on Milk Makeup, and continued underperformance could further depress the stock. There is an ongoing consideration of an in-house turnaround versus a potential asset sale for Milk Makeup, highlighting the brand's struggles.

Finally, Waldencast operates in the **highly competitive beauty and wellness industry, making it vulnerable to shifts in consumer preferences.** This sector-specific risk means the company must continuously innovate and adapt to evolving consumer tastes and market trends to maintain its relevance and market share.

AI Analysis | Feedback

null

AI Analysis | Feedback

AI Analysis | Feedback

Waldencast plc (NASDAQ: WALD), a global multi-brand beauty and wellness platform that owns Obagi Medical and Milk Makeup, is expected to drive future revenue growth over the next 2-3 years through several strategic initiatives:

1. Expansion into the Dermal Filler Market: A significant driver of future revenue growth for Waldencast is its strategic entry into the U.S. dermal filler market through the acquisition of Novaestiq Corp. and the exclusive U.S. rights to the Saypha line of hyaluronic acid injectable gels. This move is projected to double Obagi Medical's addressable market to approximately $2 billion by 2029, with the U.S. launch of Saypha products anticipated in 2026.
2. Continuous Product Innovation and Portfolio Expansion: Waldencast plans to accelerate growth through the introduction of breakthrough innovations and the expansion into new product categories for both its Obagi Medical and Milk Makeup brands. Recent examples include the launch of Obagi Medical's Nu-Cil® BioStim™ Scalp Serum and expanded Suzan Obagi MD® collection, as well as Milk Makeup's Cooling Water Jelly Tint Blush + Lip Stain.
3. Broadened Retail and Geographic Distribution: The company is focused on expanding the retail footprint and market penetration of its brands. This includes growing Milk Makeup across both brick-and-mortar and e-commerce channels in the U.S., notably through its successful launch in Ulta Beauty stores and expansion on Amazon Premium Beauty. Obagi Medical is also expected to increase its international footprint and grow its e-commerce sales.
4. Operational Efficiencies and Supply Chain Improvements: Waldencast is actively implementing supply chain transformations, including the consolidation of third-party logistics providers and optimization of its distribution center network. These strategic changes are designed to enhance operational efficiency, improve fulfillment rates for Obagi Medical, and support scalable long-term growth across the portfolio.

AI Analysis | Feedback

Share Issuance

• Waldencast's business combination with Obagi and Milk Makeup in July 2022 was partially funded by $345 million of IPO cash proceeds.
• The business combination also included $333 million from fully committed forward purchase agreements and a fully committed $105 million PIPE (Private Investment in Public Equity), which was later upsized to $118 million.
• In September 2023, Waldencast conducted a private placement, the proceeds of which were used to repay its revolving credit facility.

Inbound Investments

• The $1.2 billion business combination with Obagi and Milk Makeup in July 2022 was a significant inbound investment event, financed by IPO proceeds, forward purchase agreements, a PIPE, and $475 million in seller rollover equity from Obagi and Milk Makeup shareholders.
• A private placement in September 2023 provided capital that was used to fully repay a drawn revolving credit facility.

Outbound Investments

• In July 2022, Waldencast Acquisition Corp. completed the acquisition of Obagi Global Holdings Limited and Milk Makeup LLC, forming a multi-brand beauty and wellness platform.
• In July 2025, Waldencast expanded into medical aesthetics through the acquisition of Novaestiq and the U.S. distribution rights for Obagi® saypha® fillers.
• In November 2025, the company sold the Obagi Japan trademark rights for $82.5 million to strengthen its financial flexibility and repay debt.

Capital Expenditures

• Waldencast reported capital expenditures of approximately -$3.99 million in the last 12 months prior to March 2026.
• In 2025, Obagi incurred approximately $5.3 million in launch-related expenses for its Obagi® saypha® MagIQ™ injectables program, focusing on product, regulatory, and commercial-readiness costs.
• During the first half of 2025, Waldencast made investments in Obagi Medical for integrating Novaestiq, supply chain restructuring, and technology infrastructure optimization, and in Milk Makeup for a new international organizational structure and capital investment in fixtures for its Ulta Beauty partnership.